| Name | Title | Contact Details |
|---|
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO`s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO`s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO`s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.
Kansas Bioscience Organization is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Airway Therapeutics has extensive expertise in protein development for applications in the lungs and pediatrics.
Neuraptive is bringing novel therapeutic technology for the acute surgical repair of injured peripheral nerves.
Sangart is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.